I'm not sure it's a dead loss. One would have expected that providing a significant improvement in PFS in the liver, the only site addressed by the Sirtex product, and with 90% of mCRC patients dying of liver failure, that overall PFS would have to be improved. I wonder why that was not the case?
Ann: Preliminary SIRFLOX Study Results, page-5
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 17.3¢ | $570.1K | 3.258M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1261283 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1498416 | 36 |
View Market Depth
| Last trade - 15.42pm 26/08/2024 (20 minute delay) ? |
| SRX (ASX) Chart |